Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- MTE-6 (trace elements with selenium and iodide)
- Vitron-C-Plus (ascorbic acid/ferrous fumarate)
Interactions between your drugs
ferrous fumarate zinc sulfate
Applies to: Vitron-C-Plus (ascorbic acid/ferrous fumarate), MTE-6 (trace elements with selenium and iodide)
Iron and zinc may reduce each other's absorption when they are coadministered orally. The mechanism of interaction is unknown. In clinical studies, concurrent supplementation with iron and zinc was associated with reduced efficacy in improving the growth and iron and zinc status of malnourished infants compared to supplementation with either one alone. It is not known whether the interaction occurs in adults. In any case, the clinical significance is probably minimal in healthy individuals. However, monitoring for reduced therapeutic response may be advisable in malnourished patients. Limited data suggest that the magnitude of the interaction may be lessened by separating the times of administration of each by 12 hours.
References
- Lind T, Lonnerdal B, Stenlund H, et al. (2003) "A community-based randomized controlled trial of iron and zinc supplementation in Indonesian infants: interactions between iron and zinc." Am J Clin Nutr, 77, p. 883-90
- Sreedhar B (2003) "Conflicting evidence of iron and zinc interactions in humans: does iron affect zinc absorption?" Am J Clin Nutr, 78, 1226; author reply 1226-7
Drug and food interactions
ferrous fumarate food
Applies to: Vitron-C-Plus (ascorbic acid/ferrous fumarate)
ADJUST DOSING INTERVAL: Concomitant use of some oral medications may reduce the bioavailability of orally administered iron, and vice versa.
Food taken in conjunction with oral iron supplements may reduce the bioavailability of the iron. However, in many patients intolerable gastrointestinal side effects occur necessitating administration with food.
MANAGEMENT: Ideally, iron products should be taken on an empty stomach (i.e., at least 1 hour before or 2 hours after meals), but if this is not possible, administer with meals and monitor the patient more closely for a subtherapeutic effect. Some studies suggest administration of iron with ascorbic acid may enhance bioavailability. In addition, administration of oral iron products and some oral medications should be separated whenever the bioavailability of either agent may be decreased. Consult the product labeling for specific separation times and monitor clinical responses as appropriate.
References
- "Product Information. Feosol (ferrous sulfate)." SmithKline Beecham
- (2021) "Product Information. Accrufer (ferric maltol)." Shield Therapeutics
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.